Solving Kids Cancer Inc

Organization Overview

Solving Kids Cancer Inc is located in New York, NY. The organization was established in 2007. According to its NTEE Classification (H12) the organization is classified as: Fund Raising & Fund Distribution, under the broad grouping of Medical Research and related organizations. As of 12/2023, Solving Kids Cancer Inc employed 5 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Solving Kids Cancer Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.

For the year ending 12/2023, Solving Kids Cancer Inc generated $641.1k in total revenue. The organization has seen a slow decline revenue. Over the past 9 years, revenues have fallen by an average of (1.5%) each year. All expenses for the organization totaled $1.2m during the year ending 12/2023. As we would expect to see with falling revenues, expenses have declined by (1.3%) per year over the past 9 years. You can explore the organizations financials more deeply in the financial statements section below.

Since 2015, Solving Kids Cancer Inc has awarded 39 individual grants totaling $5,084,750. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.

Mission & Program ActivityExcerpts From the 990 Filing

TAX YEAR

2023

Describe the Organization's Mission:

Part 3 - Line 1

TO MAKE RADICAL IMPROVEMENTS IN SURVIVAL OUTCOMES FOR CHILDREN WITH THE MOST FATAL PEDIATRIC CANCERS.

Describe the Organization's Program Activity:

Part 3 - Line 4a

SKC AND OUR ADVISORS SURVEY, ACTIVELY DISCUSS, AND PRIORITIZE THE AREAS OF GREATEST UNMET NEEDS WITHIN THE PEDIATRIC CANCER RESEARCH LANDSCAPE AND DEVELOP SPECIFIC PROGRAMS TO ADDRESS THEM. (1) THE PH I TITAN CLINICAL TRIAL IS PROVIDING AN EFFECTIVE TARGETED DRUG FOR CHILDREN WITH ALK MUTATIONS IN FRONTLINE TREATMENT WHEN NEWLY DIAGNOSED AND IS GENERATING CRITICAL DATA TOWARDS AN APPROVAL FOR USE AS A STANDARD OF CARE. WORKING TOWARDS HAVING THIS BE ONE OF THE FIRST TARGETED AGENTS BECOMING APPROVED FOR HR NB AND UTILIZED AS A COMBINATION THERAPY STRATEGY, MAKING A SIGNIFICANT IMPACT ON OVERALL SURVIVAL. (2) OUR COLLABORATION WITH THE NATIONAL CANCER INSTITUTE TO VALIDATE AND DEVELOP AN IMMUNOTHERAPY TREATMENT FOR CHILDREN WITH ETMR AND MEDULLOBLASTOMA BRAIN TUMORS USING A T CELL CAR TO TARGET GPC2 IS THE FIRST EVER IMMUNOTHERAPY RESEARCH PROGRAM SPECIFIC FOR ETMR BRAIN TUMORS. IF THE RESULTS ARE POSITIVE THIS WORK WILL BE RAPIDLY TRANSLATED INTO A CLINICAL TRIAL TO INCLUDE CHILDREN WITH ETMR AS WELL AS MEDULLOBLASTOMA USING THIS CUTTING-EDGE IMMUNOTHERAPY. (3) THE PH I CLINICAL TRIAL USING A TRIPLET COMBINATION HAS BEEN A LIFELINE FOR CHILDREN WITH NEUROBLASTOMA WHO RELAPSE AND THE STUDY HAS BEEN SO SUCCESSFUL THAT IT WILL STAY OPEN TO ACCRUE EVEN MORE PATIENTS THAN ORIGINALLY PLANNED. WHILE THE CLINICAL TRIAL IS PROVIDING TREATMENT BENEFIT TO PATIENTS, THE TRIAL IS GENERATING VERY IMPORTANT DATA THAT CAN BE USED TO FURTHER ADVANCE THIS TRIPLE TREATMENT COMBINATION INTO MORE POINTS IN THE TREATMENT CONTINUUM FOR EVEN GREATER PATIENT BENEFIT. (4) SKC TARGETS ONLY THE MOST CHALLENGING AND POOREST OUTCOME CHILDHOOD CANCERS THAT REQUIRE SIGNIFICANT HELP AND HAVE THE GREATEST UNMET NEED INCLUDING HIGH-RISK BRAIN TUMORS AND SOLID TUMORS. (5) TAKES A GLOBAL APPROACH TO SUPPORTING PROGRAMS TO LEVERAGE THE COLLECTIVE POWER OF COLLABORATION ACROSS SEVERAL CENTERS-OF-EXCELLENCE TO BREAK DOWN BARRIERS, SPEED PROGRESS AND HAVE MORE CHILDREN ACCESS PROMISING TREATMENTS. (6) PRIORITIZES ADVANCING TREATMENT OPTIONS THAT HAVE THE HIGHEST POTENTIAL FOR CURATIVE RESPONSES RATHER THAN PARTIAL TUMOR SHRINKAGE OR TEMPORARY LIFE EXTENSION. (7) TAKES LEADERSHIP ROLES WITHIN INFLUENTIAL NATIONAL AND INTERNATIONAL RESEARCH GROUPS' ADVISORY BOARDS AND CO-AUTHOR INFLUENTIAL PAPERS IN PROFESSIONAL JOURNALS TO DRIVE NEW DIRECTION TO POSITIVELY IMPACT PATIENTS. (8) BUILD COALITIONS AND PARTNERSHIPS WITH OTHER NONPROFITS IN COLLABORATIVELY DRIVING AND FUNDING RESEARCH PROJECTS FOR GREATER IMPACT AND SCALE BECAUSE WE ARE MUCH MORE EFFECTIVE TOGETHER THAN WORKING ALONE. SKC PRIORITIZES THE DELIVERY OF TRANSFORMATIVE, NEXT-GENERATION CANCER THERAPIES TO THIS POPULATION THAT INCLUDES IMMUNOTHERAPY, VACCINES, CELLULAR THERAPY, ONCOLYTIC VIROTHERAPY, THERAPEUTIC ANTIBODIES, CHECKPOINT INHIBITORS, SYNERGISTIC COMBINATION TREATMENTS, NEW GENOMICALLY TARGETED DRUGS, INTERVENTIONAL RADIOLOGY TECHNIQUES AND NOVEL DELIVERY MECHANISMS. OUR CRITERIA FOR IDENTIFYING AND SUPPORTING THESE NOVEL APPROACHES AIMS TO PROVIDE MORE EFFECTIVE AND LESS TOXIC TREATMENT OPTIONS THAN THE CURRENT STANDARD-OF-CARE. (9) WE ARE PLANNING A NEW INITIATIVE FOR MEDULLOBLASTOMA TO IDENTIFY PROMISING COMBINATION THERAPIES THAT CROSS THE BLOOD-BRAIN BARRIER AS WELL AS NEW DELIVERY MECHANISMS.


Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.

Board, Officers & Key Employees

Name (title)Compensation
Scott Kennedy
Executive Di
$142,520
Khalil Barrage
Director
$0
Hearn Jay Cho
Director
$0
Diala Tabet
Director
$0
Lindy Gad
Director
$0
John London
Chair
$0

Financial Statements

Statement of Revenue
Federated campaigns$0
Membership dues$0
Fundraising events$207,063
Related organizations$0
Government grants $0
All other contributions, gifts, grants, and similar amounts not included above$450,513
Noncash contributions included in lines 1a–1f $0
Total Revenue from Contributions, Gifts, Grants & Similar$657,576
Total Program Service Revenue$0
Investment income $71,862
Tax Exempt Bond Proceeds $0
Royalties $0
Net Rental Income $0
Net Gain/Loss on Asset Sales $0
Net Income from Fundraising Events -$88,370
Net Income from Gaming Activities $0
Net Income from Sales of Inventory $0
Miscellaneous Revenue$0
Total Revenue $641,068

Grants Awarded

Over the last fiscal year, Solving Kids Cancer Inc has awarded $465,796 in support to 6 organizations.

Grant RecipientAmount

COLUMBIA UNIVERSITY

PURPOSE: CANCER RESEARCH

$5,068

THE REGENTS OF THE UNIVERSITY OF CA

PURPOSE: CANCER RESEARCH

$150,000

WEILL MEDICAL COLLEGE OF CORNELLUNIVERSITY

PURPOSE: CANCER RESEARCH

$6,228

CHILDREN'S HOSPITAL OF PHILADELPHIA

PURPOSE: CANCER RESEARCH

$162,500

NATIONAL CANCER INSTITUTE

PURPOSE: CANCER RESEARCH

$47,000

THE SWIFTY FOUNDATION

PURPOSE: CANCER RESEARCH

$95,000
View Grant Profile

Peer Organizations

Organization NameAssets
Health Effects Institute
Boston, MA
$15,080,985
Life Science Cares Inc
Cambridge, MA
$9,986,155
The Association For Frontotemporal Degeneration
King Of Prussia, PA
$8,537,416
Childrens Oncology Group Foundation
Philadelphia, PA
$7,138,252
Israel Cancer Research Fund Inc
New York, NY
$5,734,601
Hope For Depression Research Foundation
New York, NY
$6,866,948
Haymakers For Hope Inc
Wellesley, MA
$4,816,031
The Progeria Research Foundation Inc
Peabody, MA
$2,231,500
Fox Chase Cancer Center Foundation
Philadelphia, PA
$5,202,355
Improvecarenow Inc
Essex, VT
$2,946,430
The Curetivity Foundation
Darien, CT
$2,435,225
Jett Foundation Inc
Plymouth, MA
$3,537,013
Detectogether Inc
Westborough, MA
$1,930,325
The Naspghan Foundation
Ambler, PA
$1,825,546
Adenoid Cystic Carcinoma Researchfoundation
Needham, MA
$1,386,655
Zoll Foundation Inc
Chelmsford, MA
$140,621
The Pink Agenda Inc
New York, NY
$1,649,738
One Mission Inc
Newton, MA
$1,467,377
Project Purple Inc
Seymour, CT
$1,765,053
North American Neuroendocrine Tumor Society
Albany, NY
$1,085,991
The Iga Nephropathy Foundation Of America Inc
Wall, NJ
$1,466,952
Tedmed Foundation
Stamford, CT
$82,457
Dubai Harvard Foundation For Medical Research Inc
Boston, MA
$444,380
Solving Kids Cancer Inc
New York, NY
$641,068
Lifespan Extension Advocacy Foundation Inc
Seaford, NY
$1,216,278

Create an account to unlock the data you need.

or